Urinary, Renal, and Male Genitourinary Cancers

Bladder Cancer Overview and Pathophysiology

• Definition and Types:     * The most common type of bladder cancer is Transitional cell carcinomas.     * These tumors are characteristically low-grade, multifocal, and recurrent.

• Etiology and Risk Factors:     * Smoking (tobacco use) is identified as the most significant risk factor.     * Parasite infection.     * Excessive and long-term use of certain drugs.     * Exposure to environmental or occupational toxins.

• Recurrence Rate:     * Bladder cancer has the highest recurrence rate among all cancers, reaching up to $80\%$.     * Reason for recurrence: The underlying genetic changes in the tumor affect the entire urothelium. This makes the entire lining of the urinary tract more susceptible to the development of new tumors.

• Clinical Manifestations:     * Painless hematuria: This is the most common first manifestation.     * Dysuria and frequency: These symptoms typically occur if the tumor causes an infection or an obstruction.

• Labs and Diagnostics:     * Urinalysis: May show gross or microscopic hematuria.     * Bladder-wash specimen and Biopsy: These are identified as the most specific diagnostic tests.

Renal Cancer Pathophysiology and Manifestations

• Definition and Types:     * The most common type is Renal cell carcinoma.     * This cancer occurs due to impaired cellular regulation.

• Etiology and Risk Factors:     * Possible hereditary factors.     * Smoking (tobacco use).     * Exposure to certain heavy metals.     * Demographic risks: Higher incidence in men and African Americans.     * Lifestyle/Medical risks: Obesity and Hypertension ($HTN$).

• Associated Risks: Renal cell carcinoma increases the patient's risk for Chronic Kidney Disease (CKD) and various cardiovascular complications.

• Clinical Manifestations:     * Flank pain.     * Hematuria: May be bright red with clots or appear smoky/cola-colored. Hematuria is a common manifestation.     * Palpable kidney mass.     * Gynecomastia (in men).     * Pale skin.     * Late Manifestations: Muscle wasting, weakness, poor nutrition, and weight loss commonly indicate more advanced disease stages.

• Systemic Effects (Paraneoplastic Syndromes):     * Definition: Disorders triggered by an altered immune response to certain cancers. Antibodies produced to destroy cancer cells may inadvertently destroy normal cells, or cancer cells may produce substances like hormones, hormone precursors, enzymes, or cytokines.     * Diagnostic Significance: A paraneoplastic syndrome may be the first sign of cancer. The presence of typical symptoms in a patient without known cancer warrants further investigation.     * Specific Renal Paraneoplastic Syndromes:         * Anemia or Erythrocytosis: Related to alterations in the kidneys' erythropoietin production.         * Hypercalcemia: Related to the production of parathyroid hormones by the tumor cells.         * HTN: Related to the increased production of renin.         * Liver dysfunction: Related to the production of hepatotoxic hormones or enzymes by tumor cells.

• Labs and Diagnostics:     * Urinalysis: Hematuria present.     * Biochemical/Hormonal levels:         * Decreased Hemoglobin and Hematocrit ($H/H \downarrow$).         * Increased Erythrocyte Sedimentation Rate ($ESR \uparrow$).         * Increased levels of $ACTH$, $HCG$, Cortisol, Renin, and Parathyroid hormone.         * Increased blood urea nitrogen and creatinine ($BUN/Crea \uparrow$).         * Hypercalcemia.     * Imaging: CT, MRI, Ultrasound.     * Biopsy.

Management of Renal and Bladder Cancers

• Non-Surgical Management (FYI Only):     * Bladder: Prophylactic immunotherapy to prevent recurrence of superficial cancer; multi-agent chemotherapy for metastatic disease.     * Renal: Microwave ablation, cryoablation, or immunotherapy.

• Surgical Management of Bladder Cancer:     * Transurethral resection of fulguration: Used for benign tumors; involves catheterization.     * Radical cystectomy: This involves the removal of the bladder and is the usual treatment for deeper and invasive tumors. This procedure is performed in conjunction with radiation and chemotherapy.

• Surgical Management of Renal Cancer:     * Nephrectomy: The primary and usual treatment.     * Renal Artery Embolization: This procedure may be performed prior to the nephrectomy.

• Post-Surgical Nursing Priorities for Kidney Surgery:     * Hemorrhage: The kidneys are highly vascular, making hemorrhage a significant risk.     * Adrenal insufficiency: Monitored via symptoms including hypotension, decreased urine output ($UO$), altered level of consciousness ($LOC$), hyponatremia, hyperkalemia, and hypoglycemia.     * Urine Output ($UO$): Monitor for the first $24\,hours$. $30-50\,ml/hr$ is considered acceptable. Output less than $25-30\,ml/hr$ is inadequate to perfuse the remaining kidney.     * General Monitoring: Vital signs ($VS$), daily weight, $CBC$, and electrolytes. Monitor for infection and atelectasis.     * Medications: Liberal analgesics (opioids) for $3-5\,days$, antibiotics if infection is present, and steroids for adrenal insufficiency.

• Health Promotion and Education for Renal Care:     * Protect the remaining kidney: Avoid trauma and Acute Kidney Injury ($AKI$) caused by inadequate perfusion or drug toxicity.     * Risk Reduction: Smoking cessation, avoiding heavy metals, and managing obesity and $HTN$ through lifestyle changes.

Urinary Diversions (Urostomy)

• Definition: An alternative route for urine elimination after a radical cystectomy or bladder bypass.

• Incontinent Diversions:     * Ureters are surgically placed in the ileum.     * Urine is collected in an external pouch (appliance) through a stoma.     * Ileal Conduit: A conventional incontinent diversion.

• Continent Diversions:     * Urine is diverted into a surgically created internal pouch that functions as a bladder.     * The patient must perform regular self-catheterization through a stoma to remove urine.     * Indiana Pouch: Uses segments of the small and large intestines; relies on the natural ileocecal valve for continence. It has a lower risk for leaking and is the most commonly used continent diversion.     * Kock Pouch: Uses only the small intestine to create the pouch. An artificial nipple valve is created for continence; however, this type has a higher risk for leaking. It was the first continent diversion.

• Orthotopic Neobladder:     * Created from an intestinal graft.     * Characteristics: No stoma is present. Sensory nerves are not attached, so there is no sensation of bladder fullness.     * Patient Education: Patients must learn new voiding cues. Common side effects include infection and weight loss.

• Ureterosigmoidostomy:     * Diverts urine to the large intestine.     * Characteristics: No stoma required; urine is excreted during bowel movements.     * Patient Education: Men must learn new toileting practices. Bowel incontinence may occur.

• Post-Surgical Care and Nursing Implications for Diversions:     * Stoma Characteristics: The stoma has no nerve endings; it should not be a source of pain or discomfort.     * Mucus: If the intestinal tract is used for the diversion, the presence of mucus in the urine is normal.     * Dietary Restrictions: Avoid gas-producing foods, as flatus can cause bowel incontinence, especially with sigmoidostomies and conduits.     * Fluid and Electrolytes: Electrolyte replacement may be necessary; dietician consultation is recommended.     * Drainage: Monitor for and report decreased/absent drainage from nephrostomy tubes or leakage around the catheter.     * Specific Training: Enterostomal Therapist ($ET$) consultation, ostomy pouch management, and neobladder voiding cues.

Prostate Cancer

• Characteristics: Slow-growing with predictable metastasis.

• Metastasis Sites: Nearby lymph nodes, bones (pelvis, sacrum, and lumbar spine), lungs, and liver.

• Etiology and Risk Factors:     * Advanced age (over 65) is the leading risk factor.     * First-degree relative with prostate cancer.     * African American heritage.     * High serum testosterone levels.     * Dietary factors: High animal fat, high refined carbohydrates, low fiber intake.     * Vasectomy and exposure to environmental toxins.

• Clinical Manifestations:     * Difficulty starting urination, urinary retention, frequent bladder infections.     * Late symptoms: Weight loss and hematuria.     * Metastasis signs: Pain in the pelvis, spine, hips, or ribs; swollen lymph nodes in the groin.

• Labs and Diagnostics:     * DRE (Direct Rectal Examination): Findings include stony hard texture with palpable irregularities and indurations.     * Prostatic-specific antigen (PSA): Increased levels; used as a screening test. It is not a definitive diagnosis as other prostate issues increase $PSA$.     * Serum Acid Phosphatase (ACP): Increased in advanced cancer.     * Serum Alkaline Phosphatase (ALP): Increased with bone metastasis.     * Early Prostate Cancer Antigen (EPCA-2): A sensitive serum marker that may replace biopsy for diagnosis.     * Imaging: MRI (high-quality MRI is now preferred over DRE for assessment of $PSA$ changes), TRUS (transrectal ultrasound), Bone scan for metastasis, CT.

• Surgical Management:     * Laparoscopic radical prostatectomy: Associated with less pain and fewer complications.     * Open Radical Prostatectomy.     * Bilateral orchiectomy: Performed to remove the source of testosterone.

• Post-Surgical Care (Prostatectomy):     * Management of indwelling catheter.     * Continuous Bladder Irrigation (CBI): Used to prevent clot formation that leads to urinary obstruction.     * Medications: Anti-spasmodic agents for bladder spasms.     * Swelling: Elevate the scrotum and penis; apply ice for the first $24-48\,hours$.     * Long-term Complications:         * Erectile Dysfunction (ED): Due to damage/removal of cavernous nerves. Drug therapy (sildenafil) may help. Warning: Avoid concurrent use of nitrates as this can cause hypotension.         * Urge Incontinence: Due to damage to urinary sphincters; treated with Kegel perineal exercises.

Testicular Cancer

• Characteristics: Usually curable with early detection via testicular self-examination ($TSE$).

• Types: Germ-cell seminoma is the most common type with a good prognosis. It is rarely bilateral; if bilateral, it usually indicates metastasis rather than a second primary cancer.

• Risk Factors:     * Undescended testis (cryptorchidism).     * HIV infection.     * Family/Personal history.     * Caucasian race (higher risk than other ethnicities).

• Clinical Manifestations:     * Painless enlargement of the testis.     * Metastasis signs: Testicular pain, abdominal mass, bone pain, lymph node swelling, hydrocele (fluid in scrotum), and gynecomastia.

• Labs and Diagnostics:     * Markers: Increased Alpha-fetoprotein ($AFP$), beta-human chorionic gonadotropin ($hCG$), lactate dehydrogenase ($LDH$), and serum testosterone.     * Sperm quality: Oligospermia (low count) or azoospermia (absence of living sperm) due to high testicular temperature from cancer cell metabolism.     * Inguinal orchiectomy: Used to confirm the diagnosis.

• Management:     * Reproductive Options: Sperm banking must be done before treatment. Donor insemination or adoption are alternatives.     * Surgical Options: Laparoscopic orchiectomy (less pain) or Open Orchiectomy and radical retroperitoneal lymph node dissection ($RPLND$).

• Teaching: Scrotal support, dressing care, and instruction on Testicular Self-Examination (TSE).